OBJECTIVE:Detecting significant fibrosis and cirrhosis remains important in treatment and follow-up of patients with chronic hepatitis C Infection (CHC). The aim of this study was to assess the ability of PRO-C3 to identify significant fibrosis (Ishak score ≥3) and cirrhosis (Ishak score ≥5) both as a single test and as a part of algorithms.
MATERIALS AND METHODS:PRO-C3 was assessed in baseline samples from the NORDynamIC trial. 270 patients were stratified into groups according to baseline biopsy. Baseline APRI, FIB-4 and GUCI scores were available for comparison in 232 patients.
RESULTS:PRO-C3 increased with Ishak scores (p = .001). Area under the curve (AUC) for significant fibrosis was 0.75 (95% CI 0.68-0.81) and 0.76 (95% CI 0.68-0.84) for cirrhosis. FIB-4, APRI and GUCI had similar AUCs. In a PRO-C3 algorithm including age, platelet count, body mass index (BMI) and international normalised ratio (INR), the diagnostic efficacy improved to 0.85 (CI 0.80-0.89) and 0.90 (IQR 0.84-0.96) for significant fibrosis and cirrhosis, respectively.
CONCLUSIONS:In our study, PRO-C3 was an independent predictor of fibrosis stage, and may play an important role in managing CHC patients.
October 25, 2017
Scand J Gastroenterol
Hansen JF, Nyström K, Leeming DJ, Lagging M, Norkrans G, Brehm Christensen P, Karsdal MA, Nielsen MJ
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.